Southpoint Capital Advisors LP Fennec Pharmaceuticals Inc. Transaction History
Southpoint Capital Advisors LP
- $3.45 Billion
- Q1 2025
A detailed history of Southpoint Capital Advisors LP transactions in Fennec Pharmaceuticals Inc. stock. As of the latest transaction made, Southpoint Capital Advisors LP holds 4,077,214 shares of FENC stock, worth $35.7 Million. This represents 0.72% of its overall portfolio holdings.
Number of Shares
4,077,214
Previous 4,077,214
-0.0%
Holding current value
$35.7 Million
Previous $25.8 Million
3.64%
% of portfolio
0.72%
Previous 0.71%
Shares
2 transactions
Others Institutions Holding FENC
# of Institutions
71Shares Held
13.9MCall Options Held
10KPut Options Held
83.8K-
Sonic Gp LLC Honolulu, HI2.41MShares$21.1 Million33.54% of portfolio
-
Solas Capital Management, LLC Darien, CT2.25MShares$19.7 Million9.62% of portfolio
-
Black Rock Inc. New York, NY1.19MShares$10.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA965KShares$8.44 Million0.0% of portfolio
-
Harbert Fund Advisors, Inc. Birmingham, AL467KShares$4.09 Million3.22% of portfolio
About FENNEC PHARMACEUTICALS INC.
- Ticker FENC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,067,300
- Market Cap $228M
- Description
- Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...